Numerai GP LLC Acquires 2,059 Shares of Humana Inc. (NYSE:HUM)

Numerai GP LLC raised its stake in Humana Inc. (NYSE:HUM - Free Report) by 40.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,145 shares of the insurance provider's stock after purchasing an additional 2,059 shares during the period. Numerai GP LLC's holdings in Humana were worth $1,813,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares during the period. Dodge & Cox boosted its position in shares of Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after acquiring an additional 5,264,045 shares during the period. Pzena Investment Management LLC boosted its position in shares of Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after acquiring an additional 1,103,132 shares during the period. Geode Capital Management LLC boosted its position in shares of Humana by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock valued at $729,658,000 after acquiring an additional 63,562 shares during the period. Finally, Invesco Ltd. boosted its position in shares of Humana by 29.8% in the fourth quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock valued at $608,348,000 after acquiring an additional 550,692 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HUM. Barclays boosted their target price on shares of Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a research report on Friday, April 11th. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. Mizuho upped their price objective on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Raymond James raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Finally, StockNews.com raised shares of Humana from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Seventeen analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Humana presently has an average rating of "Hold" and a consensus price target of $286.81.

Humana Price Performance

Shares of HUM stock traded up $9.95 on Friday, reaching $237.42. The company had a trading volume of 2,548,740 shares, compared to its average volume of 1,765,981. The stock has a market capitalization of $28.65 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a one year low of $212.45 and a one year high of $406.46. The business's 50-day moving average is $262.94 and its 200 day moving average is $269.47.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $7.23 earnings per share. Equities research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.49%. The ex-dividend date is Friday, June 27th. Humana's payout ratio is 25.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.